Donor nonclassical monocytes initiate lung injury following transplantation
供体非经典单核细胞在移植后引发肺损伤
基本信息
- 批准号:10542738
- 负责人:
- 金额:$ 55.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdoptive TransferAffectAllograftingAlveolarAntibodiesAntigensBindingBiologyCX3CL1 geneCXCL2 geneChemotactic FactorsChronicClinicalContralateralDataDevelopmentDistantEndothelial CellsEndotheliumExtravasationFractalkineFunctional disorderGeneticGrowthHourHumanHypoxemic Respiratory FailureIL1R1 geneInflammasomeInjuryIntegrinsInterleukin-1 betaLeukocytesLoxP-flanked alleleLungLung TransplantationLymphocyteMediatingMembraneMolecularMusMutateNR4A1 geneNeutrophil InfiltrationNuclear Orphan ReceptorOrganOutcomePathway interactionsPatient-Focused OutcomesPatientsPerfusionPermeabilityPreventionProductionPublishingPulmonary InflammationReperfusion InjuryReperfusion TherapyReportingResistanceRisk FactorsRoleSignal PathwaySignal TransductionSolidSpecificitySyndromeSystemTLR2 geneTechniquesTherapeuticTight JunctionsTissuesToll-like receptorsToxic effectTranscriptTransplantationUp-RegulationVascular PermeabilitiesVascularizationcadherin 5clinical applicationexperienceexperimental studyfractalkine receptorgraft dysfunctionimprovedinsightlung developmentlung injurylung ischemiamigrationmonocytemortalitymouse modelneutrophilnovelpathogenpharmacologicpost-transplantpreservationpulmonary functionreconstitutionrecruitsuccess
项目摘要
The indications for lung transplantation have expanded significantly, resulting in a clinical growth of over 50%
in the last decade. However, the survival following lung transplant is the worst compared to other solid organs
with only 80% and 50% of patients alive at 1 and 5 years, respectively. Primary graft dysfunction (PGD),
resulting from ischemia-reperfusion injury, affects over 50% of recipients within 24 hours of transplantation and
has emerged as the most important risk factor for both short-term mortality as well as long-term graft loss from
chronic rejection. As such, therapies directed to ameliorate PGD have the highest potential for improving lung
transplant outcomes. Prior reports have demonstrated that recruitment and extravasation of neutrophils into
the allograft is necessary for the development of PGD. Depleting neutrophils can ameliorate PGD, but is not
clinically feasible given their importance in pathogen clearance. Accordingly, we have focused on
understanding the mechanisms that drive neutrophil recruitment to the lung following transplantation. We
discovered that orphan nuclear receptor (NR4A1)-dependent non-classical monocytes (NCM), characterized
by CD14dimCD16++ in humans and Ly6ClowCX3CR1highCCR2- in mice, are bound to the pulmonary endothelium
via a leukocyte integrin (lymphocyte factor associated antigen-1) and retained in the donor lungs despite the
current techniques for organ perfusion. Following murine and human lung transplant, activated donor-derived
NCM mediate neutrophil recruitment and extravasation into the allograft through mechanisms that remain
unknown. Our published and preliminary data suggest that activation of toll-like receptors in donor-derived
NCM leads to the production of neutrophil chemoattractant, macrophage inflammatory protein 2 (MIP-2). The
donor NCM also release IL-1 and contribute to enhanced vascular permeability in the allograft. Importantly,
using a genetic lineage tracing system we found that donor-derived NCM also migrate to distant organs after
transplant where they recruit neutrophils. Collectively, these data support our hypothesis that donor-derived
NCM are activated following lung ischemia-reperfusion, drive neutrophil influx into the allograft, and promote
secondary injury to distant organs. We have developed a model of murine vascularized orthotopic lung
transplantation where lungs from NR4A1-deficient donor mice, which selectively lack NCM, can be
reconstituted with fluorescent wild-type or genetically mutated NCM to study the signaling pathways in
donor-derived NCM and their contribution to lung IRI. Accordingly, we will dissect the molecular
mechanisms underlying NCM-mediated injury in the allograft and bystander tissues. We will determine: 1) The
toll-like receptors responsible for the activation of donor NCM, 2) Mechanisms through which donor NCM
migrate to distant organs and mediate bystander injury, 3) The role of inflammasome-dependent production of
IL-1 by NCM in mediating neutrophil extravasation. Through these experiments, we will identify pathways that
could be clinically targeted, prior to transplantation, to ameliorate PGD without causing recipient toxicity.
肺移植的适应症已显著扩大,导致临床增长超过50%
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ankit Bharat其他文献
Ankit Bharat的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ankit Bharat', 18)}}的其他基金
Role of spleen educated monocytes in mediating ischemia-reperfusion injury followinglung transplant surgery
脾脏单核细胞在介导肺移植术后缺血再灌注损伤中的作用
- 批准号:
10661445 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Role of Spleen educated monocytes in mediating ischemia-reperfusion injury following lung transplant
脾脏单核细胞在介导肺移植后缺血再灌注损伤中的作用
- 批准号:
9900589 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Donor nonclassical monocytes initiate lung injury following transplantation
供体非经典单核细胞在移植后引发肺损伤
- 批准号:
10318938 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Pathogenesis of lung injury mediated by lung-restricted antibodies
肺限制性抗体介导的肺损伤的发病机制
- 批准号:
10372131 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Role of Spleen educated monocytes in mediating ischemia-reperfusion injury following lung transplant
脾脏单核细胞在介导肺移植后缺血再灌注损伤中的作用
- 批准号:
9765907 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Pathogenesis of lung injury mediated by lung-restricted antibodies
肺限制性抗体介导的肺损伤的发病机制
- 批准号:
10673371 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Role of Spleen educated monocytes in mediating ischemia-reperfusion injury following lung transplant
脾脏单核细胞在介导肺移植后缺血再灌注损伤中的作用
- 批准号:
10374787 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Role of Spleen educated monocytes in mediating ischemia-reperfusion injury following lung transplant
脾脏单核细胞在介导肺移植后缺血再灌注损伤中的作用
- 批准号:
10132385 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Pathogenesis of lung injury mediated by lung-restricted antibodies
肺限制性抗体介导的肺损伤的发病机制
- 批准号:
9900583 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Donor nonclassical monocytes initiate lung injury following transplantation
供体非经典单核细胞在移植后引发肺损伤
- 批准号:
10093127 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 55.12万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 55.12万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 55.12万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 55.12万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 55.12万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 55.12万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 55.12万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 55.12万 - 项目类别:














{{item.name}}会员




